drugset / Trial / NCT00292747

Drotaverine in Dysmenorrhoea Treatment

NCT00292747

Phase 4 Terminated 480 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and secondary dysmenorrhoea.

Timeline

Start
2005-05-25
Primary completion
2006-02-28
Completion
2006-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Drotaverine Small molecule 80 mg Oral
Comparator Ibuprofen Small molecule 400 mg Oral

Indications